ROVI Pharmaceuticals Laboratories 
Welcome,         Profile    Billing    Logout  
 4 Products   41 Diseases   4 Products   152 Trials   6863 News 


«12...7891011121314151617...8889»
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    New P2 trial:  Heart Failure Polypill at a Safety Net Hospital (clinicaltrials.gov) -  Sep 8, 2023   
    P2,  N=40, Not yet recruiting, 
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Enrollment open, Trial completion date, Trial initiation date:  DAPAPROTECTOR: DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction (clinicaltrials.gov) -  Sep 8, 2023   
    P3,  N=450, Recruiting, 
    Advancing the knowledge of the pathophysiology of HHD will consolidate effective risk stratification and personalized treatment through a multimodal manner integrating complementary CMR and biomarkers into the conventional care approach.Clinical Trial Registration: ClinicalTrials.gov, identifier, NCT03553810. Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Initiation date: Mar 2023 --> Jun 2023
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Trial completion:  PARACOR-19: Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 (clinicaltrials.gov) -  Sep 6, 2023   
    P1/2,  N=42, Completed, 
    Furthermore, AF and the ventricular tachyarrhythmia rate were revealed more in obesity compared with those without obesity at the 12-month follow-up. Active, not recruiting --> Completed
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal:  Changes in Mid-regional Pro-adrenomedullin during treatment with Sacubitril/Valsartan. (Pubmed Central) -  Aug 31, 2023   
    P2, P4
    Change in MR-proADM from neprilysin inhibition did not correlate with improvements in cardiac structure and function or health status. More data are needed regarding the role of adrenomedullin and its related peptides in the treatment of heart failure.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal:  Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. (Pubmed Central) -  Aug 29, 2023   
    In this article, we review the evolution of the pillar concept of therapy as it applies to DKD and discuss how it should be used based on the outcome evidence. We also discuss the exciting possibility that GLP-1 RAs may be an additional pillar in the quest to further slow kidney disease progression in diabetes.
  • ||||||||||  perindopril arginine / Generic mfg.
    Journal:  ARNI Versus Perindopril for Remodeling in HFrEF. A Cohort Study. (Pubmed Central) -  Aug 28, 2023   
    Both ARNI and perindopril yielded a significant improvement in the LVEF within 9 months. The remodeling effect of ARNI seems stronger because of the greater improvements in left ventricular volumes.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal:  Importance of the 'area under the curve' from serial NT-proBNP measurements during treatment with sacubitril/valsartan. (Pubmed Central) -  Aug 26, 2023   
    The remodeling effect of ARNI seems stronger because of the greater improvements in left ventricular volumes. Serial NT-proBNP monitoring (integrating the totality of measurements as an AUC) during treatment with sacubitril/valsartan informs unique information regarding the future changes in cardiac remodelling indices, especially among those with higher NT-proBNP levels at baseline.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Enrollment status, Trial completion date, Trial primary completion date:  PDD in Type 2 Diabetes w/wo Diastolic Dysfunction (clinicaltrials.gov) -  Aug 24, 2023   
    P2,  N=80, Recruiting, 
    Serial NT-proBNP monitoring (integrating the totality of measurements as an AUC) during treatment with sacubitril/valsartan informs unique information regarding the future changes in cardiac remodelling indices, especially among those with higher NT-proBNP levels at baseline. Enrolling by invitation --> Recruiting | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Preclinical, Journal:  Qiliqiangxin capsule improves cardiac remodeling in rats with DOCA-salt-induced diastolic dysfunction. (Pubmed Central) -  Aug 22, 2023   
    Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02924727. QL improved the cardiac function and inhibited the myocardial fibrosis in DOCA salt-induced rat HFpEF by improving diastolic dysfunction, preventing left ventricular hypertrophy, and ameliorating the inflammatory responses model in DOCA salt-induced rat HFpEF model.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Review, Journal:  Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. (Pubmed Central) -  Aug 14, 2023   
    This study highlights the importance of considering HFrEF and NAFLD when developing treatment plans for patients with these comorbidities. Further research is needed in patients with coexisting HFrEF and NAFLD, with an emphasis on novel therapies and the importance of a multidisciplinary approach for managing these complex comorbidities.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Enrollment closed, Trial completion date, Trial primary completion date:  The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans (clinicaltrials.gov) -  Aug 14, 2023   
    P4,  N=90, Active, not recruiting, 
    Further research is needed in patients with coexisting HFrEF and NAFLD, with an emphasis on novel therapies and the importance of a multidisciplinary approach for managing these complex comorbidities. Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Jun 2024 | Trial primary completion date: Aug 2023 --> Jan 2024
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Successful C-Section Delivery at 36 Weeks in a Patient With a Heartmate 3 LVAD (Zone 2, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_6043;    
    Low-dose digoxin was added for right ventricular support... Pregnancy during LVAD support remains an extremely high-risk clinical situation, though this case demonstrates that it is possible to carry such a pregnancy to near-term.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Trends in the Utilization of Sacubitril/Valsartan by Cardiologists: A Safety-Net Hospital Experience (Zone 2, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_5666;    
    Despite the robust evidence supporting the benefit of using Sacubitril/Valsartan in HF and the unique opportunity that Cardiologists have in taking ownership in optimizing HF management; our data seems to suggest that prescription rates of Sacubitril/Valsartan by Cardiologists at our institution remains low when compared to other specialties. This may contribute to an undertreatment of high-risk HF patients.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Stress-Induced Cardiomyopathy After Uncomplicated Permanent Pacemaker Implantation (Zone 2, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_5238;    
    In the absence of typical cardiac symptoms after PPM implantation, a poor general condition may also be considered as a sign of SCMP. Therefore, it is necessary to monitor the patient for at least three more days after PPM implantation.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Chemotherapy in Pregnancy: Assessing the Safety of Adriamycin Administration in Pregnancy Complicated by Breast Cancer (Zone 4, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_5073;    
    This case demonstrates the importance of multidisciplinary patient management, particularly for those with low LVEF who are at higher risk of decompensation. Despite not knowing the etiology of PABC, she could be suffering from thrombotic microangiopathy of small coronary vessels, which explains relief from nitrates.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Cardiac Structure and Function Predict Incident Atrial Fibrillation and Flutter in Patients With HFpEF - Lessons From PARAGON-HF (Zone 2, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_4483;    
    Furthermore, higher (better) LA reservoir strain (LAsr) (HR: 0.66 per 10.8%, 95% CI: 0.48-0.92, p=0.014) and LA contractile strain (absolute LAsct) (HR: 0.71 per 6.7%, 95% CI: 0.51-0.98, p=0.040) predicted lower risk of incident AFF. Conclusions In the PARAGON-HF echocardiographic sub-study, worse diastolic and LA function, larger LA size and higher LV mass were associated with a higher risk of incident AFF.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Age-Related Echocardiographic Characteristics in Patients With Heart Failure With Preserved Ejection Fraction in PARAGON-HF (Zone 2, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_2843;    
    After adjusting for sex, race, region, history of MI, diabetes, AF, and body mass index, every 10 years of increase in age was associated with 5.1 mL/m2 decrease in LV end-diastolic volume index (95% confidence interval [CI] 3.9 - 6.5, p < 0.001), 0.4% increase in absolute global longitudinal strain (95% CI 0.1% - 0.7%, p = 0.017), and 1.07 increase in E/e' septal ratio (95% CI 0.42 - 1.73, p = 0.001).Conclusions Compared with younger patients, older patients with HFpEF were more likely to be female with AF, have better systolic function and higher LV filling pressure. These findings demonstrated the heterogeneity in cardiac structure and function in HFpEF by age and may have implications for treatment and future clinical trial recruitment.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Review, Journal:  Sacubitril/valsartan-induced liver injury: A case report and literature review. (Pubmed Central) -  Aug 11, 2023   
    Sacubitril/valsartan-induced liver injury is very rare. Clinicians should pay particular attention to the possibility of hepatotoxicity during sacubitril/valsartan treatment.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Kerendia (finerenone) / Bayer
    Review, Journal:  Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials. (Pubmed Central) -  Aug 10, 2023   
    Other potential pharmacotherapies represented by non-steroidal mineralocorticoid receptor antagonists finerenone and antifibrotic agent pirfenidone also hold promise for the treatment of HFpEF. This article intends to review the clinical evidence on current pharmacotherapies of HFpEF, as well as the comorbidities management of atrial fibrillation, hypertension, T2DM, obesity, pulmonary hypertension, renal insufficiency, obstructive sleep apnea, and iron deficiency, to optimize the clinical management of HFpEF.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal:  The use of sacubitril/valsartan in Takotsubo syndrome with severe impairment of left ventricular systolic function. (Pubmed Central) -  Aug 9, 2023   
    This article intends to review the clinical evidence on current pharmacotherapies of HFpEF, as well as the comorbidities management of atrial fibrillation, hypertension, T2DM, obesity, pulmonary hypertension, renal insufficiency, obstructive sleep apnea, and iron deficiency, to optimize the clinical management of HFpEF. No abstract available